We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Can Silver Replace Platinum for Chemotherapy?

By LabMedica International staff writers
Posted on 23 Feb 2012
Bidentate silver compounds (where a ligand is bound to the central silver atom through two sites) were found to be more effective anticancer agents than were those where the ligand was coordinated through only one site (monodentate).

Recorded use of silver to prevent infection dates to ancient Greece and Rome; it was rediscovered in the Middle Ages when it was used for several purposes, such as to disinfect water and food during storage, and also for the treatment of burns and wounds as wound dressing. More...
Silver solutions were approved in the 1920s by the [US] Food and Drug Administration for use as antibacterial agents.

The most common metal used in chemotherapeutic agents is platinum. Despite severe adverse side effects, which include kidney and nerve damage and nausea, cisplatin remains the drug of choice for treatment of many types of cancer, with about half of all cancer patients receiving platinum-based chemotherapy. Another drawback of conventional cisplatin treatment is the drug’s relatively short lifetime in the bloodstream. Only about 1% percent of the dose given to a patient reaches the target cells, and about half the dose is excreted within an hour of treatment.

In a preliminary study to test the suitability of silver compounds for use in chemotherapy, investigators at the University of Leeds (United Kingdom) cultured breast and colon cancer cells with different silver-based chemicals for six-day periods. They reported in the January 6, 2012, online edition of the journal Dalton Transactions that several cationic silver complexes bearing bis(N-heterocyclic carbene) ligands exhibited cytotoxicity comparable to cisplatin. Bidentate ligands showed enhanced cytotoxicity over monodentate and macrocyclic ligands.

The enhanced cytotoxicity of the bidentate compounds may have been be due to protracted release of the silver atoms, which made these compounds more effective over a longer period of time.

First author Dr. Charlotte Willans, a chemistry research fellow at the University of Leeds, said, “As many are unfortunately aware, chemotherapy can be a very grueling experience for the patient. Finding effective, yet nontoxic drugs is an ongoing problem, but these preliminary results are an important step in solving it. Our research has looked at the structure, which surrounds a central silver atom. This “shrubbery” is what determines how reactive it is and what it will interact with. Our research has used different types of these ligands to see which is the most effective against cancer cells.”

Related Links:

University of Leeds




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.